Found: 55
Select item for more details and to access through your institution.
Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study
- Published in:
- ACR Open Rheumatology, 2022, v. 4, n. 10, p. 903, doi. 10.1002/acr2.11487
- By:
- Publication type:
- Article
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 5, p. 408, doi. 10.1002/cpdd.251
- By:
- Publication type:
- Article
A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy.
- Published in:
- Clinical Pharmacology in Drug Development, 2016, v. 5, n. 4, p. 259, doi. 10.1002/cpdd.237
- By:
- Publication type:
- Article
Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making.
- Published in:
- Patient Preference & Adherence, 2020, v. 14, p. 119, doi. 10.2147/PPA.S220714
- By:
- Publication type:
- Article
Simulating clinical trial visits yields patient insights into study design and recruitment.
- Published in:
- Patient Preference & Adherence, 2017, v. 11, p. 1295, doi. 10.2147/PPA.S137416
- By:
- Publication type:
- Article
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.
- Published in:
- Rheumatology, 2007, v. 46, n. 7, p. 1122, doi. 10.1093/rheumatology/kem033
- By:
- Publication type:
- Article
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases.
- Published in:
- Rheumatology, 2007, v. 46, n. 7, p. 1122, doi. 10.1093/rheumatology/kem033
- By:
- Publication type:
- Article
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 2, p. 499, doi. 10.1007/s10067-021-05894-2
- By:
- Publication type:
- Article
General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo‐Controlled Trials.
- Published in:
- Arthritis Care & Research, 2022, v. 74, n. 6, p. 918, doi. 10.1002/acr.24637
- By:
- Publication type:
- Article
Brief Report: Safety and Immunogenicity of Rituximab Biosimilar GP 2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Twice Daily Versus Once Nightly Dosing of Pregabalin for Fibromyalgia: A Double-Blind Randomized Clinical Trial of Efficacy and Safety.
- Published in:
- Arthritis Care & Research, 2014, v. 66, n. 2, p. 293, doi. 10.1002/acr.22111
- By:
- Publication type:
- Article
Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study.
- Published in:
- Arthritis Care & Research, 2013, v. 65, n. 5, p. 718, doi. 10.1002/acr.21876
- By:
- Publication type:
- Article
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
- Published in:
- Arthritis Research & Therapy, 2015, v. 17, n. 1, p. 1, doi. 10.1186/s13075-015-0612-7
- By:
- Publication type:
- Article
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- Published in:
- Arthritis Research & Therapy, 2015, v. 17, n. 1, p. 95, doi. 10.1186/s13075-015-0612-7
- By:
- Publication type:
- Article
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee.
- Published in:
- Arthritis Research & Therapy, 2011, v. 13, n. 4, p. 1, doi. 10.1186/ar3430
- By:
- Publication type:
- Article
Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
- Published in:
- Rheumatology, 2024, v. 63, n. 4, p. 1058, doi. 10.1093/rheumatology/kead333
- By:
- Publication type:
- Article
Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis.
- Published in:
- Rheumatology, 2023, v. 62, n. 10, p. 3268, doi. 10.1093/rheumatology/kead062
- By:
- Publication type:
- Article
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients.
- Published in:
- Rheumatology, 2022, v. 61, n. 3, p. 1035, doi. 10.1093/rheumatology/keab449
- By:
- Publication type:
- Article
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up.
- Published in:
- Rheumatology, 2020, v. 59, n. 2, p. 292, doi. 10.1093/rheumatology/kez265
- By:
- Publication type:
- Article
Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebocontrolled PALACE 4 trial.
- Published in:
- Rheumatology, 2018, v. 57, n. 7, p. 1253, doi. 10.1093/rheumatology/key032
- By:
- Publication type:
- Article
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
- Published in:
- Rheumatology, 2017, v. 56, n. 9, p. 1498, doi. 10.1093/rheumatology/kex174
- By:
- Publication type:
- Article
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study.
- Published in:
- ACR Open Rheumatology, 2020, v. 2, n. 2, p. 119, doi. 10.1002/acr2.11102
- By:
- Publication type:
- Article
Assessing usability, label comprehension, pen robustness and pharmacokinetics of a selfadministered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis.
- Published in:
- SAGE Open Medicine, 2014, v. 2, p. 1, doi. 10.1177/2050312114564241
- By:
- Publication type:
- Article
Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 2, p. 168, doi. 10.1002/jcph.239
- By:
- Publication type:
- Article
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study.
- Published in:
- Arthritis & Rheumatology, 2021, v. 73, n. 1, p. 110, doi. 10.1002/art.41477
- By:
- Publication type:
- Article
The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double‐Blind, Placebo‐Controlled, Randomized Clinical Trial.
- Published in:
- Arthritis & Rheumatology, 2019, v. 71, n. 11, p. 1824, doi. 10.1002/art.41012
- By:
- Publication type:
- Article
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2017, v. 69, n. 12, p. 2283, doi. 10.1002/art.40319
- By:
- Publication type:
- Article
Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2017, v. 69, n. 5, p. 932, doi. 10.1002/art.40054
- By:
- Publication type:
- Article
Blockade of Interferon-γ Normalizes Interferon-Regulated Gene Expression and Serum CXCL10 Levels in Patients With Systemic Lupus Erythematosus.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 10, p. 2713, doi. 10.1002/art.39248
- By:
- Publication type:
- Article
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 6, p. 1424, doi. 10.1002/art.39093
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis.
- Published in:
- Arthritis & Rheumatology, 2015, v. 67, n. 2, p. 334, doi. 10.1002/art.38949
- By:
- Publication type:
- Article
A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment.
- Published in:
- Arthritis & Rheumatology, 2014, v. 66, p. S218, doi. 10.1002/art.38595
- By:
- Publication type:
- Article
Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 4, p. 668, doi. 10.1093/mr/roac084
- By:
- Publication type:
- Article
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
- Published in:
- Modern Rheumatology, 2022, v. 32, n. 2, p. 263, doi. 10.1093/mr/roab030
- By:
- Publication type:
- Article
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 3, p. 675, doi. 10.1007/s40744-024-00666-1
- By:
- Publication type:
- Article
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 1, p. 53, doi. 10.1007/s40744-022-00498-x
- By:
- Publication type:
- Article
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
- Published in:
- Rheumatology & Therapy, 2022, v. 9, n. 5, p. 1361, doi. 10.1007/s40744-022-00474-5
- By:
- Publication type:
- Article
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.
- Published in:
- Rheumatology & Therapy, 2021, v. 8, n. 4, p. 1775, doi. 10.1007/s40744-021-00380-2
- By:
- Publication type:
- Article
Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis.
- Published in:
- Rheumatology & Therapy, 2020, v. 7, n. 4, p. 775, doi. 10.1007/s40744-020-00226-3
- By:
- Publication type:
- Article
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
- Published in:
- Rheumatology & Therapy, 2020, v. 7, n. 3, p. 553, doi. 10.1007/s40744-020-00209-4
- By:
- Publication type:
- Article
Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study.
- Published in:
- Rheumatology & Therapy, 2020, v. 7, n. 1, p. 101, doi. 10.1007/s40744-019-00182-7
- By:
- Publication type:
- Article
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
- Published in:
- Rheumatology & Therapy, 2019, v. 6, n. 4, p. 503, doi. 10.1007/s40744-019-00167-6
- By:
- Publication type:
- Article
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study.
- Published in:
- Rheumatology & Therapy, 2019, v. 6, n. 3, p. 393, doi. 10.1007/s40744-019-0163-5
- By:
- Publication type:
- Article
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
- Published in:
- Rheumatology & Therapy, 2018, v. 5, n. 2, p. 447, doi. 10.1007/s40744-018-0123-5
- By:
- Publication type:
- Article
Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.
- Published in:
- Rheumatology & Therapy, 2018, v. 5, n. 2, p. 341, doi. 10.1007/s40744-018-0113-7
- By:
- Publication type:
- Article
Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials.
- Published in:
- Pain & Therapy, 2019, v. 8, n. 2, p. 271, doi. 10.1007/s40122-019-0125-1
- By:
- Publication type:
- Article
Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article